111 related articles for article (PubMed ID: 8693647)
1. Bropirimine immunotherapy of upper urinary tract carcinoma in situ.
Sarosdy MF; Pisters LL; Carroll PR; Benson MC; Moon TD; Lamm DL; Hudson MA; Lerner SP; Koch MO; Schellhammer PF
Urology; 1996 Jul; 48(1):28-32. PubMed ID: 8693647
[TBL] [Abstract][Full Text] [Related]
2. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.
Sarosdy MF; Lowe BA; Schellhammer PF; Lamm DL; Graham SD; Grossman HB; See WA; Peabody JO; Moon TD; Flanigan RC; Crawford ED; Morganroth J
Urology; 1996 Jul; 48(1):21-7. PubMed ID: 8693646
[TBL] [Abstract][Full Text] [Related]
3. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.
Witjes WP; König M; Boeminghaus FP; Hall RR; Schulman CC; Zurlo M; Fittipaldo A; Riggi M; Debruyne FM
Eur Urol; 1999 Dec; 36(6):576-81. PubMed ID: 10559611
[TBL] [Abstract][Full Text] [Related]
4. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():20-6. PubMed ID: 9076482
[TBL] [Abstract][Full Text] [Related]
5. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.
Sarosdy MF; Manyak MJ; Sagalowsky AI; Belldegrun A; Benson MC; Bihrle W; Carroll PR; Ellis WJ; Hudson MA; Sharkey FE
Urology; 1998 Feb; 51(2):226-31. PubMed ID: 9495702
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
[TBL] [Abstract][Full Text] [Related]
8. [Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):77-85. PubMed ID: 9020949
[TBL] [Abstract][Full Text] [Related]
9. [Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2049-53. PubMed ID: 10584570
[TBL] [Abstract][Full Text] [Related]
10. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Furue H; Machida T; Masaoka T; Ikeda S
Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
[TBL] [Abstract][Full Text] [Related]
11. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ.
Studer UE; Casanova G; Kraft R; Zingg EJ
J Urol; 1989 Oct; 142(4):975-7. PubMed ID: 2795755
[TBL] [Abstract][Full Text] [Related]
13. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter.
Irie A; Iwamura M; Kadowaki K; Ohkawa A; Uchida T; Baba S
Urology; 2002 Jan; 59(1):53-7. PubMed ID: 11796281
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of oral bropirimine in superficial bladder cancer.
Sarosdy MF; Lamm DL; Williams RD; Moon TD; Flanigan RC; Crawford ED; Wilks NE; Earhart RH; Merritt JA
J Urol; 1992 Jan; 147(1):31-3. PubMed ID: 1729546
[TBL] [Abstract][Full Text] [Related]
16. Ureteral carcinoma in situ at radical cystectomy: does the margin matter?
Silver DA; Stroumbakis N; Russo P; Fair WR; Herr HW
J Urol; 1997 Sep; 158(3 Pt 1):768-71. PubMed ID: 9258077
[TBL] [Abstract][Full Text] [Related]
17. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
18. Radical nephroureterectomy as initial treatment for carcinoma in situ of upper urinary tract.
Yuasa T; Tsuchiya N; Narita S; Inoue T; Saito M; Kumazawa T; Horikawa Y; Matsuura S; Satoh S; Nanjo H; Habuchi T
Urology; 2006 Nov; 68(5):972-5. PubMed ID: 17095072
[TBL] [Abstract][Full Text] [Related]
19. Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.
Inamoto T; Matsuyama H; Ibuki N; Komura K; Takahara K; Fujimoto K; Shiina H; Sakano S; Nagao K; Miyake M; Tatsumi Y; Yasumoto H; Azuma H;
J Urol; 2018 Apr; 199(4):933-939. PubMed ID: 29037861
[TBL] [Abstract][Full Text] [Related]
20. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Borden EC; Sidky YA; Ertürk E; Wierenga W; Bryan GT
Cancer Res; 1990 Feb; 50(4):1071-4. PubMed ID: 2297754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
